A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice

Vaccine

Volumn 33, Issue 14, 2015, Pages 1702-1710

  Hunsawong, Taweewun ^a,b   Sunintaboon, Panya ^a   Warit, Saradee ^c   Thaisomboonsuk, Butsaya ^b   Jarman, Richard G ^d   Yoon, In Kyu ^b   Ubol, Sukathida ^a   Fernandez, Stefan ^b  

^a Mahidol University   (Thailand)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Dengue nanovaccine; Dengue virus; Immunostimulatory effect; Nanoparticle based vaccine; Swiss albino mice

Indexed keywords

CHEMOKINE; CHITOSAN; DENGUE NANOVACCINE; DENGUE VACCINE; EOTAXIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 5; NANOPARTICLE; NEUTRALIZING ANTIBODY; RANTES; UNCLASSIFIED DRUG; CYTOKINE; VIRUS ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL CELL WALL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENGUE VIRUS 2; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG; NONHUMAN; PRIORITY JOURNAL; SWISS WEBSTER MOUSE; ULTRAVIOLET RADIATION; VIRUS INACTIVATION; VIRUS STRAIN; ANIMAL; BLOOD; DENGUE; DENGUE VIRUS; IMMUNOLOGY; SEROTYPE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CHITOSAN; CYTOKINES; DENGUE; DENGUE VACCINES; DENGUE VIRUS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; MICE; MYCOBACTERIUM BOVIS; NANOPARTICLES; SEROGROUP; ULTRAVIOLET RAYS;

EID: 84925273732     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.02.016     Document Type: Article

References (61)

1. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496:504-507.
2. Erlandsson J., McQuaid C.D., Skold M. Patchiness and co-existence of indigenous and invasive mussels at small spatial scales: the interaction of facilitation and competition. PLoS ONE 2011, 6:e26958.
3. Vaughan K., Greenbaum J., Blythe M., Peters B., Sette A. Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology. Viral Immunol 2010, 23:259-284.
4. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:7229-7241.
5. Poo J., Galan F., Forrat R., Zambrano B., Lang J., Dayan G.H. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2010, 30(1):e9-e17.
6. Guy B., Saville M., Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccine 2010, 16(9):696-705.
7. Maves R.C., Castillo Ore R.M., Porter K.R., Kochel T.J. Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice. Clin Vaccine Immunol 2010, 17:304-306.
8. Eckels K.H., Putnak R. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv Virus Res 2003, 61:395-418.
9. Chiang C.Y., Hsieh C.H., Chen M.Y., Tsai J.P., Liu H.H., Liu S.J., et al. Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity. Vaccine 2014, 32:1346-1353.
10. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
11. Chua A.J., Vituret C., Tan M.L., Gonzalez G., Boulanger P., Ng M.L., et al. A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies. Virol J 2013, 10:129.
12. Arora U., Tyagi P., Swaminathan S., Khanna N. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice. Vaccine 2013, 31:873-878.
13. Zhang Z.S., Yan Y.S., Weng Y.W. Construction of sub-unit dengue vaccines and analysis of its immunogenicity. Zhonghua shi yan he lin chuang bing du xue za zhi=Zhonghua shiyan he linchuang bingduxue zazhi 2010, 24:430-432.
14. Batra G., Gurramkonda C., Nemani S.K., Jain S.K., Swaminathan S., Khanna N. Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris. J Biosci Bioeng 2010, 110:408-414.
15. Gustin J.K., Douglas J.L., Bai Y., Moses A.V. Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain. J Biol Chem 2012, 287:14837-14850.
16. + T cells following uptake by human APC. J Immunol 2004, 172:1595-1601.
17. Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384:1358-1365.
18. Martin J., Crossland G., Wood D.J., Minor P.D. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 2003, 84:1781-1788.
19. Duque H., Marshall R.L., Israel B.A., Letchworth G.J. Effects of formalin inactivation on bovine herpes virus-1 glycoproteins and antibody response elicited by formalin-inactivated vaccines in rabbits. Vaccine 1989, 7:513-520.
20. Clatts M.C., Goldsamt L.A., Yi H. An emerging HIV risk environment: a preliminary epidemiological profile of an MSM POZ Party in New York City. Sex Transm Infect 2005, 81:373-376.
21. Maves R.C., Ore R.M., Porter K.R., Kochel T.J. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. Vaccine 2011, 29:2691-2696.
22. Ramirez R., Falcon R., Izquierdo A., Garcia A., Alvarez M., Perez A.B., et al. Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design. Virus Genes 2014, 49(2):185-195.
23. Hao J., Wang F., Wang X., Zhang D., Bi Y., Gao Y., et al. Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. Eur. J. Pharm. Sci. 2012, 47:497-505.
24. Ban I., Stergar J., Drofenik M., Ferk G., Makovec D. Synthesis of chromium-nickel nanoparticles prepared by a microemulsion method and mechanical milling. Acta Chim Sloven 2013, 60:750-755.
25. Arpornwichanop T., Polpanich D., Thiramanas R., Suteewong T., Tangboriboonrat P. PMMA-N,N,N-trimethyl chitosan nanoparticles for fabrication of antibacterial natural rubber latex gloves. Carbohydr Polym 2014, 109:1-6.
26. Petukhova N.V., Gasanova T.V., Stepanova L.A., Rusova O.A., Potapchuk M.V., Korotkov A.V., et al. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors. Curr Pharm Des 2013, 19:5587-5600.
27. Gagliardi M.C., Teloni R., Mariotti S., Iona E., Pardini M., Fattorini L., et al. Bacillus Calmette-Guerin shares with virulent Mycobacterium tuberculosis the capacity to subvert monocyte differentiation into dendritic cell: implication for its efficacy as a vaccine preventing tuberculosis. Vaccine 2004, 22:3848-3857.
28. Buse J., El-Aneed A. Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances. Nanomedicine (Lond) 2010, 5:1237-1260.
29. Wang B., Rosano J.M., Cheheltani R., Achary M.P., Kiani M.F. Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin Drug Deliv 2010, 7:1159-1173.
30. Neuhaus V., Chichester J.A., Ebensen T., Schwarz K., Hartman C.E., Shoji Y., et al. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung. Vaccine 2014, 32:3216-3222.
31. Sawaengsak C., Mori Y., Yamanishi K., Mitrevej A., Sinchaipanid N. Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine. AAPS PharmSciTech 2014, 15:317-325.
32. Mori Y., Ono T., Miyahira Y., Nguyen V.Q., Matsui T., Ishihara M. Antiviral activity of silver nanoparticle/chitosan composites against H1N1 influenza A virus. Nanoscale Res Lett 2013, 8:93.
33. Lv S., Wang J., Dou S., Yang X., Ni X., Sun R., et al. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection. Hepatology 2014, 59:385-394.
34. Prego C., Paolicelli P., Diaz B., Vicente S., Sanchez A., Gonzalez-Fernandez A., et al. Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine 2010, 28:2607-2614.
35. Uehori J., Fukase K., Akazawa T., Uematsu S., Akira S., Funami K., et al. Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. J Immunol 2005, 174:7096-7103.
36. Yoshikai Y., Ohga S., Takeda Y., Nomoto K. Effects of stimulated or immunologically activated macrophages on the induction of immune responses to Listeria monocytogenes. Immunobiology 1990, 180:124-137.
37. Hrabak A., Bajor T., Csuka I. The effect of various inflammatory agents on the phagocytosis and cytokine profile of mouse and rat macrophages. Inflam Res 2008, 57:75-83. (official journal of the European Histamine Research Society [et al].).
38. Inphonlek S., Pimpha N., Sunintaboon P. Synthesis of poly(methyl methacrylate) core/chitosan-mixed-polyethyleneimine shell nanoparticles and their antibacterial property. Colloids Surf, B: Biointerfaces 2010, 77:219-226.
39. Homhuan A., Kogure K., Akaza H., Futaki S., Naka T., Fujita Y., et al. New packaging method of mycobacterial cell wall using octaarginine-modified liposomes: enhanced uptake by and immunostimulatory activity of dendritic cells. J Controlled Release 2007, 120:60-69.
40. Thaisomboonsuk B.K., Clayson E.T., Pantuwatana S., Vaughn D.W., Endy T.P. Characterization of dengue-2 virus binding to surfaces of mammalian and insect cells. Am J Trop Med Hyg 2005, 72:375-383.
41. Yue H., Wei W., Fan B., Yue Z., Wang L., Ma G., et al. The orchestration of cellular and humoral responses is facilitated by divergent intracellular antigen trafficking in nanoparticle-based therapeutic vaccine. Pharmacol Res 2012, 65:189-197.
42. Cardosa M.J., Tio P.H., Nimmannitya S., Nisalak A., Innis B. IgM capture ELISA for detection of IgM antibodies to dengue virus: comparison of 2 formats using hemagglutinins and cell culture derived antigens. Southeast Asian J Trop Med Public Health 1992, 23:726-729.
43. Duangchinda T., Dejnirattisai W., Vasanawathana S., Limpitikul W., Tangthawornchaikul N., Malasit P., et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 2010, 107(39):16922-16927.
44. Thomas S.J., Nisalak A., Anderson K.B., Libraty D.H., Kalayanarooj S., Vaughn D.W., et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 2009, 81:825-833.
45. McMichael A.J., Rowland-Jones S.L. HIV. Bad news for stop-start therapy?. Nature 2002, 420(371):3.
46. Kong X., Hellermann G.R., Zhang W., Jena P., Kumar M., Behera A., et al. Chitosan interferon-gamma nanogene therapy for lung disease: modulation of t-cell and dendritic cell immune responses. Allergy, Asthma, Clin Immunol 2008, 4:95-105. (official journal of the Canadian Society of Allergy and Clinical Immunology.).
47. Altaf H., Revell P.A. Evidence for active antigen presentation by monocyte/macrophages in response to stimulation with particles: the expression of NFkappaB transcription factors and costimulatory molecules. Inflammopharmacology 2013, 21:279-290.
48. Lindow J.C., Borochoff-Porte N., Durbin A.P., Whitehead S.S., Fimlaid K.A., Bunn J.Y., et al. Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. PLoS Negl Trop Dis 2012, 6:e1742.
49. Perez A.B., Sierra B., Garcia G., Aguirre E., Babel N., Alvarez M., et al. Tumor necrosis factor-alpha, transforming growth factor-beta1, and interleukin-10 gene polymorphisms: implication in protection or susceptibility to dengue hemorrhagic fever. Hum Immunol 2010, 71:1135-1140.
50. Becquart P., Wauquier N., Nkoghe D., Ndjoyi-Mbiguino A., Padilla C., Souris M., et al. Acute dengue virus 2 infection in Gabonese patients is associated with an early innate immune response, including strong interferon alpha production. BMC Infect Dis 2010, 10:356.
51. Perry S.T., Buck M.D., Lada S.M., Schindler C., Shresta S. STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog 2011, 7:e1001297.
52. Guabiraba R., Marques R.E., Besnard A.G., Fagundes C.T., Souza D.G., Ryffel B., et al. Role of the chemokine receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice. PLoS ONE 2010, 5:e15680.
53. de Cassan S.C., Pathan A.A., Sander C.R., Minassian A., Rowland R., Hill A.V., et al. Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A. Clin Vaccine Immunol 2010, 17:1066-1073.
54. Guabiraba R., Besnard A.G., Marques R.E., Maillet I., Fagundes C.T., Conceicao T.M., et al. IL-22 modulates IL-17A production and controls inflammation and tissue damage in experimental dengue infection. Eur J Immunol 2013, 43:1529-1544.
55. Tan G.K., Ng J.K., Trasti S.L., Schul W., Yip G., Alonso S. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 2010, 4:e672.
56. Brown M.G., McAlpine S.M., Huang Y.Y., Haidl I.D., Al-Afif A., Marshall J.S., et al. RNA sensors enable human mast cell anti-viral chemokine production and IFN-mediated protection in response to antibody-enhanced dengue virus infection. PLoS ONE 2012, 7:e34055.
57. King C.A., Anderson R., Marshall J.S. Dengue virus selectively induces human mast cell chemokine production. J Virol 2002, 76:8408-8419.
58. Valdes I., Bernardo L., Gil L., Pavon A., Lazo L., Lopez C., et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009, 394:249-258.
59. Thomas S.J., Hombach J., Barrett A. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 2009, 27:355-368.
60. Weiskopf D., Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol 2014, 5:93.
61. Cheng X., Zengel J.R., Suguitan A.L., Xu Q., Wang W., Lin J., et al. Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets. J Infect Dis 2013, 208:594-602.